Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INO

INO - Inovio Pharmaceuticals Inc Stock Price, Fair Value and News

$1.67-0.01 (-0.60%)
Market Closed

8/100

INO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

INO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

INO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INO Price Action

Last 7 days

-4.0%

Last 30 days

3.7%

Last 90 days

-18.9%

Trailing 12 Months

-13.5%

INO RSI Chart

INO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INO Valuation

Market Cap

115.4M

Price/Earnings (Trailing)

-1.36

Price/Sales (Trailing)

1.8K

EV/EBITDA

-0.85

Price/Free Cashflow

-1.3

INO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

INO Fundamentals

INO Revenue

Revenue (TTM)

65.3K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

INO Earnings

Earnings (TTM)

-84.9M

Earnings Growth (Yr)

119.66%

Earnings Growth (Qtr)

108.38%

INO Profitability

EBT Margin

-130000.00%

Return on Equity

-352.34%

Return on Assets

-114.25%

Free Cashflow Yield

-77.06%

INO Investor Care

Shares Dilution (1Y)

88.43%

Diluted EPS (TTM)

-1.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025283.1K182.3K182.3K65.3K
20244.2M2.1M1.7M1.7M
202312.3M13.7M4.9M4.9M
20222.7M2.7M11.5M10.8M
20218.3M8.2M7.6M2.8M
20202.6M3.5M3.6M8.9M
201931.8M7.5M6.3M4.1M
201839.3M36.4M33.4M30.5M
201737.6M51.8M41.9M42.2M
201643.5M44.4M32.8M35.4M
201513.3M14.8M37.1M40.6M
201414.4M17.4M9.7M10.5M
20133.9M4.2M12.9M13.5M
20128.4M6.4M4.6M4.1M
20117.9M9.2M10.5M9.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Inovio Pharmaceuticals Inc

INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
 CEO
 WEBSITEinovio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES135

Inovio Pharmaceuticals Inc Frequently Asked Questions

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Inovio Pharmaceuticals Inc is 115.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, INO's PE ratio (Price to Earnings) is -1.36 and Price to Sales (PS) ratio is 1.77 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.32 (multiply by 100 for percentage) rate of return.